Human Metabolome Technologies, Chugai Pharmaceutical to Collaborate in Biomarker Search.

Tokyo, Japan, Sept 15, 2005 - (JCNN JCNN Japan Corporate News Network ) - Human Metabolome Technologies (HMT HMT Her Majesty's Treasury (UK)
HMT Hazardous Materials Table (49 CFR 172.101)
HMT Health Management Technology (magazine)
HMT Higher Mother Tongue
HMT Hindustan Machine Tools Ltd. ) and Chugai Pharmaceutical jointly have signed a collaborative research agreement, whereby the two companies will strive to identify biomarkers for hepatic and renal diseases using HMT's proprietary metaboome analysis technologies.

Human Metabolome Technologies, which was founded by Keio University Keio University (慶應義塾大学 Keiō gijuku daigaku in July 2003, is a bioventure company specializing in metabolomics.

Source: JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.

COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	JCNN News Summaries
Date:	Sep 16, 2005
Words:	75
Previous Article:	Aun Consulting Forecasts Content-Targeted Advertising Market Trend.
Next Article:	Bridgestone Develops Support Ring-type Runflat System.

Related Articles
A big circuit model.(Metabonomics)
Metabolomics--a new exciting field within the "omics" sciences.(Guest Editorial)
Metabolomics: what's happening downstream of DNA.(Focus)
National Institute of Technology and Evaluation, Astellas Pharma, Chugai Pharmaceutical to Collaborate in Searching Microorganisms in Vietnam.
Chugai Pharmaceutical to Spin off Production Operations.
Chugai Files NDA for an Anti-Tumor Agent, Erlotinib (Epidermal Growth Factor Receptor (EGFR/HER1) Tyrosine Kinase Inhibitor).
Chugai Announces Japanese Phase III Trial Data Demonstrates Efficacy of 'Actemra(R),' a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, on...
Chugai Announces Co-Development and Co-Marketing Agreement with Taisho Pharmaceutical for the Antiresorptive Bisphosphonate R484.
Chugai to Launch HIV Protease Inhibitor INVIRASE(R) Tablet 500mg on September 15.
Chugai Pharmaceutical to Establish an Oncology Unit.